Krijn Dijkstra

The Netherlands Cancer Institute
Country flagNetherlands

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (21)

Cancer is a highly heterogeneous disease, with many cancers containing multiple distinct subclones. While subclones are often seen as competitors (survival of the fittest), intratumor heterogeneity can also offer direct benefits to the tumor through cooperation between different clones. This has important clinical implications, as interdependent populations may present therapeutic vulnerabilities. Here, we review existing evidence for clonal cooperativity to address key questions and outline future developments based on six overarching principles: (a) secreted factors are important mediators of clonal cooperation; (b) (very) small subclones can significantly affect tumor behavior; (c) both genetic and nongenetic heterogeneity are substrates for cooperation; (d) nonmalignant cells from the tumor microenvironment can act as cooperating partners; (e) clonal cooperation occurs throughout different stages of cancer, from premalignancy to metastasis; and (f) clonal cooperation can promote therapy resistance by protecting otherwise sensitive populations. Together, these principles suggest clonal cooperation as an important mechanism in cancer. Lastly, we discuss how novel technological developments could address remaining gaps to open up new therapeutic strategies that exploit clonal cooperativity by targeting the tumor's weakest link.

Year:

2026

Studies have identified a link between specific microbiome-derived bacteria and immune checkpoint blockade (ICB) efficacy. However, these species lack consistency across studies, and their immunomodulatory mechanisms remain elusive. To understand the influence of the microbiome on ICB response, we studied its functional capacity. Using pan-cancer metagenomics data from ICB-treated patients, we showed that community-level metabolic pathways are stable across individuals, making them suitable for predicting ICB response. We identified several microbial metabolic processes significantly associated with response, including the methylerythritol 4-phosphate (MEP) pathway, which was associated with response and induced Vδ2 T cell–mediated antitumor responses in patient-derived tumor organoids. In contrast, riboflavin synthesis was associated with ICB resistance, and its intermediates induced mucosal-associated invariant T (MAIT) cell–mediated immune suppression. Moreover, gut metabolomics revealed that high riboflavin levels were linked to worse survival in patients with abundant intratumoral MAIT cells. Collectively, our results highlight the relevance of metabolite-mediated microbiome–immune cell cross-talk. Significance: Microbial metabolic pathways are highly conserved across individuals and therefore offer an opportunity to link the microbiome to immunotherapy efficacy. We identified specific microbial metabolic pathways associated with response to ICB and provided mechanistic insights into the immunomodulatory influence of these pathways on antitumor immunity.

Year:

2026

Studies have identified a link between specific microbiome-derived bacteria and immune checkpoint blockade (ICB) efficacy. However, these species lack consistency across studies, and their immunomodulatory mechanisms remain elusive. To understand the influence of the microbiome on ICB response, we studied its functional capacity. Using pan-cancer metagenomics data from ICB-treated patients, we showed that community-level metabolic pathways are stable across individuals, making them suitable for predicting ICB response. We identified several microbial metabolic processes significantly associated with response, including the methylerythritol 4-phosphate (MEP) pathway, which was associated with response and induced Vδ2 T cell–mediated antitumor responses in patient-derived tumor organoids. In contrast, riboflavin synthesis was associated with ICB resistance, and its intermediates induced mucosal-associated invariant T (MAIT) cell–mediated immune suppression. Moreover, gut metabolomics revealed that high riboflavin levels were linked to worse survival in patients with abundant intratumoral MAIT cells. Collectively, our results highlight the relevance of metabolite-mediated microbiome–immune cell cross-talk. Significance: Microbial metabolic pathways are highly conserved across individuals and therefore offer an opportunity to link the microbiome to immunotherapy efficacy. We identified specific microbial metabolic pathways associated with response to ICB and provided mechanistic insights into the immunomodulatory influence of these pathways on antitumor immunity.

Year:

2025

IMC workflow defines the single-cell spatial landscape of the NSCLC tumor microenvironment. A, TRACERx 100 IMC cohort. We developed and applied two IMC antibody panels, Pan-immune and T cells and stroma, to tissue microarrays (TMA) from clinical samples collected at surgical resection (created with BioRender.com). B, Targets of antibodies described in this study. Bold text indicates targets detected in both IMC panels. C, IMC data were acquired from stained TMAs and processed to identify single cells and their phenotypes. D, 40,000 μm 2 crops of IMC images representing the markers from B with corresponding cell types from the pan-immune panel, unless annotated with an asterisk for the T cells and stroma panel only. E, A heat map of the z-score normalized median intensities of markers from the pan-immune panel across the identified cell subtypes. F, Proportion of major immune cell types identified in the pan-immune IMC data set per TMA core, calculated over the total tissue area (illustrated as blue and gold domains), tumor/epithelial compartment (gold domain), or the stromal compartment (blue domain). In two normal cores, the epithelial cell signal reflected very thin cells, which were not resolved into an epithelial compartment. All data from these cores are represented by the stroma compartment. Cell types color legend applies to D and F , where asterisks denote cell types identified in T cells and stroma panel only. LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; NSCLC, non–small cell lung cancer; other, other non–small cell lung cancer histologies; IMC, imaging mass cytometry.

Year:

2024

Neutrophil infiltration is associated with recent subclonal expansion and poorer disease-free survival. A, Comparison of neutrophil cell density in primary tumors with metastasis-seeding clones detectable at time of surgery or during follow-up (metastasizing tumors) to tumors from patients who were metastasis-free and recurrence-free for more than 3 years of follow-up time (control) in LUAD ( n = 28) and LUSC ( n = 15) within the TRACERx discovery cohort. Maximum neutrophil density taken for tumors with multiple tumor cores. P values derived from one-tailed Wilcoxon test. B, Kaplan–Meier curves for DFS according to tumor-level TAN score in the validation cohort ( n = 332 patients). P value derived from univariate Cox model adjusted for histology. C, Multivariable Cox proportional hazard regression analysis of DFS using tumor-level TAN score and tumor-level necrosis evaluation from H&E images of diagnostic tumor blocks. D, Recent subclonal expansion score, measured as the maximum cancer cell fraction of subclones at the terminus of the phylogenetic tree, compared between TAN-high and TAN-low tumor regions in LUAD and LUSC patients from the TRACERx 421 cohort. P values were derived from a linear mixed effects model with patient as random effect. E, Spatial ITH score of cell types and communities and ITH probabilities of TME classes in multiregion analysis (pan-immune n = 41 tumors, 112 cores). ITH score was calculated as the average standard deviation of the cell/community density in multiple regions per tumor and z-score transformed. ITH score of αSMA + cells was derived from T cells and stroma panel ( n = 39 tumors, 105 cores). ITH probability was calculated as 1 − probability of all regions having the same indicated TME class. F, Example phylogenetic tree depicting a stage IIIA LUSC case with a clonal PIK3CA mutation, high TAN scores, and recent subclonal expansion, including in a region (R5) that seeded a lymph node (LN) metastasis (FLN, FFPE LN). The metastasis-seeding lineage is highlighted in orange. Tumor-level TAN scores and regional subclonal expansion (SubExp) scores are reported for primary tumor regions. The reported TAN score represents the maximum of the tumor nest and stroma scores. Each cluster in the phylogenetic tree is assigned a color that is also represented in the region clone maps. The clone maps illustrate the prevalence of each clone within a region. G, IMC images shown for R5 and the LN metastasis. Scale bar, 200 μm. H, Summary schematic of the link between tumors with a neutrophil enriched microenvironment with tumor progression. · , P P P P

Year:

2024

Supplementary Figures 1-22 with the corresponding figure legends inline. Supplementary Figure S1. TRACERx 100 imaging mass cytometry cohort. Supplementary Figure S2. Analysis of imaging mass cytometry data. Supplementary Figure S3. Characterisation of cell subtypes and spatial cellular communities in non-small cell lung cancer. Supplementary Figure S4. Clinicogenomic correlations with cell subtypes and communities. Supplementary Figure S5. TME class associations with cell types and clinical variables. Supplementary Figure S6. Cancer cell-intrinsic and -extrinsic features associated with immune cell infiltration. Supplementary Figure S7. Spatial, histological and metabolic features of the Tumour/Stroma:Neutrophil High TME class. Supplementary Figure S8. Transcriptomic features of TS:Neutrophil High TME class and Tumour-Associated Neutrophil scoring. Supplementary Figure S9. Somatic mutations in PIK3CA were associated with neutrophil recruitment through CXCL8 upregulation. Supplementary Figure S10. TAN score association with disease-free survival. Supplementary Figure S11. Validation of the prognostic association from the TAN scoring approach with an automated, deep learning approach in The Cancer Genome Atlas. Supplementary Figure S12. Imaging mass cytometry panel development. Supplementary Figure S13. Spillover matrices for imaging mass cytometry data. Supplementary Figure S14. Multiplexed Consensus Cell Segmentation. Supplementary Figure S15. Investigation of batch effects. Supplementary Figure S16. Raw pixel intensities. Supplementary Figure S17. Pathologist-guided labels. Supplementary Figure S18. Communities methodology and histology associations. Supplementary Figure S19. Multiplexed immunohistochemistry validation of checkpoint molecule expression. Supplementary Figure S20. Cell-cell relationships differ by TME class. Supplementary Figure S21. Cell-cell relationships differ by tumour genomics. Supplementary Figure S22. Cell-cell relationships based on tumour cell phenotypes.

Year:

2024

Neutrophil-rich TMEs are associated with activating mutations in PI3K and tumor-intrinsic CXCL8 upregulation. A, Representative crops of tumor-level H&E images with low TAN scores in the tumor nest and stroma (left) and high TAN scores in the tumor nest and stroma (right), inferred as the proportion of the neutrophil area in tumor/stroma from the total tumor/stroma tissue area. Scale bar, 50 μm; 400× magnification. B, Neutrophil cell density as defined by IMC compared between region-level TAN-low versus TAN-high tumor cores based on H&E scores in LUAD and LUSC. C and D, Proportion of tumor cores with (mut) and without (wt) PIK3CA driver mutations compared between TS:Neutrophil high versus other TME classes combined ( C ) and region-level TAN-High versus TAN-Low cores ( D ) in LUSC. P values were derived from a Chi-square test. E, Neutrophil cell density by PIK3CA mutation status, points colored by TME class assignment. F and G, TMM expression values for CXCL8 compared by PIK3CA mutation status ( F ) and between TME classes ( G ) in LUSC. H, Immunofluorescence images of CXCL8 RNAscope multiplexed with antibody staining of pancytokeratin (panCK) or MPO in an LUSC tumor region with a TS:Neutrophil high TME and subclonal PIK3CA mutation, and an LUSC patient with multiple TAN-high tumor regions and a clonal PIK3CA mutation. panCK and MPO examples for CRUK0075:R2 illustrate the same region of interest, whereas different regions of interest are shown for CRUK0468:R6. Scale bar, 100 μm. P values for B and E were calculated in a linear mixed-effects model with patient as the random-effect covariate. P values in F and G were derived from a limma–voom differential expression analysis correcting for multiple regions per tumor. · , P P P P M -values; TS, tumor/stroma; TIL, tumor-infiltrating lymphocyte; MΦ, macrophage; TAN, tumor-associated neutrophils; H&E, hematoxylin and eosin; mt, mutant; wt, wild-type.

Year:

2024

Neutrophil infiltration in LUSC is associated with distinct metabolic and immunosuppressive phenotypes. A, Gene Ontology (GO) biological processes enriched among upregulated genes in the TS:Neutrophil high TME class ( n = 10 cores) compared with other TME classes combined ( n = 28 cores) in LUSC (FDR 0.05). B, GSEA of hallmark gene sets compared between tumor cores from the Tumor/Stroma:Neutrophil high TME class and other TME classes combined, using the t-statistic derived from the limma–voom model on TMM-normalized gene expression. Significantly enriched pathways were colored by type of pathway (FDR C, Normalized enrichment score derived from single-sample GSEA visualized for TS:Neutrophil high and cores from other TME classes. The P value is derived from GSEA of LUSC as shown in A and adjusted for other hallmark pathways using the Benjamini–Hochberg method. D, Proportion of tumor cells assigned MCT4 + in TS:Neutrophil high tumor cores compared with tumor cores from other TME classes combined in LUSC. E, Spearman correlation coefficient and P value comparing the proportion of MCT4 + and CAIX + tumor cells in TS:Neutrophil high LUSC TMEs. F, Median distance between LUSC tumor cells to their nearest endothelial cell per core in TS:Neutrophil high TME class compared with all other TME classes combined. G, Single-channel images and composite image alongside cell type map displaying tumor cells, neutrophils (MPO, yellow), endothelial cells (CD31, magenta), and regions of hypoxia (CAIX, cyan) and MCT4 (green) expression. Boxplots show median and lower and upper quartile values, and whiskers extend up to 1.5 × IQR above and below the quartiles. P values for D and F were calculated in a linear mixed-effects model with patient as the random-effect covariate. LUSC, lung squamous cell carcinoma; TS, tumor/stroma; FDR, false discovery rate; TMM, trimmed mean of M -values; panCK, pancytokeratin; *, P P P

Year:

2024

Supplementary Table S1. Imaging mass cytometry antibody panel information. Supplementary Table S2. TRACERx 100 imaging mass cytometry cohort information. Supplementary Table S3. TRACERx 421 cohort information. Supplementary Table S4. Median cell densities per histology, tissue type and TME class. Supplementary Table S5. Multivariable model of disease-free survival including TAN score, relevant clinical features together with PIK3CA mutation status (a) or recent subclonal expansion (b).

Year:

2024

Neutrophil infiltration in LUSC is associated with distinct metabolic and immunosuppressive phenotypes. A, Gene Ontology (GO) biological processes enriched among upregulated genes in the TS:Neutrophil high TME class ( n = 10 cores) compared with other TME classes combined ( n = 28 cores) in LUSC (FDR 0.05). B, GSEA of hallmark gene sets compared between tumor cores from the Tumor/Stroma:Neutrophil high TME class and other TME classes combined, using the t-statistic derived from the limma–voom model on TMM-normalized gene expression. Significantly enriched pathways were colored by type of pathway (FDR C, Normalized enrichment score derived from single-sample GSEA visualized for TS:Neutrophil high and cores from other TME classes. The P value is derived from GSEA of LUSC as shown in A and adjusted for other hallmark pathways using the Benjamini–Hochberg method. D, Proportion of tumor cells assigned MCT4 + in TS:Neutrophil high tumor cores compared with tumor cores from other TME classes combined in LUSC. E, Spearman correlation coefficient and P value comparing the proportion of MCT4 + and CAIX + tumor cells in TS:Neutrophil high LUSC TMEs. F, Median distance between LUSC tumor cells to their nearest endothelial cell per core in TS:Neutrophil high TME class compared with all other TME classes combined. G, Single-channel images and composite image alongside cell type map displaying tumor cells, neutrophils (MPO, yellow), endothelial cells (CD31, magenta), and regions of hypoxia (CAIX, cyan) and MCT4 (green) expression. Boxplots show median and lower and upper quartile values, and whiskers extend up to 1.5 × IQR above and below the quartiles. P values for D and F were calculated in a linear mixed-effects model with patient as the random-effect covariate. LUSC, lung squamous cell carcinoma; TS, tumor/stroma; FDR, false discovery rate; TMM, trimmed mean of M -values; panCK, pancytokeratin; *, P P P

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (17)

Philip Hobson

Deputy Head of Flow Cytometry

The Francis Crick Institute

UNITED KINGDOM
View details

Mihaela Angelova

The Francis Crick Institute

UNITED KINGDOM
View details

Charles Swanton

Chief Clinician

-

UNITED KINGDOM
View details

Lodewyk Wessels

Professor

Delft University of Technology

NETHERLANDS
View details

Julian Downward

Associate Research Director

The Francis Crick Institute

UNITED KINGDOM
View details

Boudewijn Burgering

University Medical Center Groningen

NETHERLANDS
View details

Mariam Jamal-Hanjani

Group Leader and Thoracic Oncologist

University College London

UNITED KINGDOM
View details

Clare Puttick

The Francis Crick Institute

UNITED KINGDOM
View details

Selvaraju Veeriah

University College London

UNITED KINGDOM
View details

JAMES READING

University College London

UNITED KINGDOM
View details

Katey Enfield

Assistant Professor

The University of British Columbia

CANADA
View details

Allan Hackshaw

University College London

UNITED KINGDOM
View details

Marcel de Zoete

University Medical Center Groningen

NETHERLANDS
View details

Hans Gelderblom

Prof.dr

Leiden University Medical Center

NETHERLANDS
View details

Sergio Quezada

University College London

UNITED KINGDOM
View details

Erik Sahai

The Francis Crick Institute

UNITED KINGDOM
View details

Mary Green

Deputy Head of Experimental Histopathology

The Francis Crick Institute

UNITED KINGDOM
View details